AccessClosure Signs Distribution Agreement to Enter Into UK, Switzerland and France

Growth of Mynx Device Continues in International Markets

MOUNTAIN VIEW, California, May 17, 2011 - AccessClosure, Inc., the market segment leader in extravascular closure
devices, announced today an exclusive agreement with Biosensors International
for the distribution of the Mynx(TM) Vascular Closure Device throughout the
United Kingdom, Switzerland and France. The extravascular Mynx device,
designed for patient comfort while providing hemostasis without sutures or
implants, will be sold as part of Biosensors' interventional cardiology
product range.

"These European countries represent a meaningful market opportunity for
us, and we are pleased to be able to partner with Biosensors' established
sales force for the distribution of Mynx," said Gregory D. Casciaro,
President and CEO of AccessClosure. "Distribution in international markets is
a key component of AccessClosure's growth strategy, and provides an excellent
complement to our direct sales presence in the United States."

Biosensors will join AccessClosure's existing and growing global network
of distributors. Biosensors is now the fifth largest drug-eluting stent (DES)
supplier globally, marketing its BioMatrix(TM) family of DES systems which
offer the unique combination of Biolimus A9(TM), an anti-restenotic drug
developed by Biosensors exclusively for use with DES, and an
abluminally-coated biodegradable polymer. Biosensors has a well established
direct presence in the UK, Switzerland and France, and will provide
AccessClosure with broad and rapid access to those markets.

"We are pleased to offer the Mynx device as part of our interventional
cardiology product range" said Jeffrey B. Jump, CEO of Biosensors. "The Mynx
device, paired with our portfolio of drug-eluting and bare-metal stents,
allows us to offer a more complete solution to our customers. The Mynx has
had great success in the United States and other international markets, and
we anticipate similar success in these European countries."

The Mynx Vascular Closure Device utilizes a conformable, water-soluble
polyethylene glycol (PEG) sealant to immediately seal the femoral artery.
Dissolving within 30 days, Mynx leaves nothing behind but a healed artery.
The extravascular device is designed for increased patient comfort and
clinical versatility. The Mynx, which received its first FDA approval in May
2007, has been used in over 800,000 procedures to date.

About AccessClosure, Inc.

Founded in 2002, AccessClosure, Inc. is a privately held medical device
company pioneering innovative access site management products designed to
provide a reliable, patient-friendly vascular closure experience. For more
information, please visit our website at www.accessclosure.com/

About Biosensors International

Biosensors International develops, manufactures and markets innovative
medical devices used in interventional cardiology and critical care
procedures. With the increasing use of the BioMatrix(TM) family of
drug-eluting stent systems, we are rapidly emerging as a leader in the global
coronary stent market. For more information, please visit www.biosensors.com .

Jennifer Jones of AccessClosure, Inc., +1-408-482-3660, jjones at accessclosure.com